PAREXEL Informatics Strengths, Domain Expertise, and Key Differentiators
Perceptive Informatics has been leading the life sciences apps marketplace by completing more than 500 integration projects to connect disparate applications across clinical technology systems provided by multiple vendors. PAREXEL introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight 6.0. and IMPACT Express Clinical Trial Management System (CTMS), a cost-effective clinical trial management solution to simplify clinical trial management and monitoring for small to mid-sized biopharmaceutical companies.
PAREXEL and EMC Corporation have allied to offer an end-to-end Regulatory Information Management (RIM) and Regulatory Content Management solution. By combining the PAREXEL LIQUENT InSight Regulatory Information Management platform and EMC Documentum for Life Sciences software solution suite, PAREXEL will provide life sciences companies with a complete solution for a product's entire regulatory lifespan. The offering is available through PAREXEL's Regulatory Cloud.
PAREXEL Informatics Recent Developments
In October 2018 PAREXEL developed several new solutions that take a patient-centric approach to address drug development. Built on the Perceptive Cloud platform and leveraging PAREXEL's relationship with Microsoft, the solutions incorporate mobile and wearable technology to increase access to data and improve the patient experience in clinical research.
The first solution is designed to enable health care staff and first-line clinicians to communicate time-sensitive events to study staff. Leveraging Microsoft Azure App Services, the technology will generate health alerts through data transmission from mobile devices, gathered at the patient home or in the field and forwarded automatically whenever there is connectivity. Staff and investigators will then be automatically informed and could proactively address any threat to patient safety, potentially decreasing the risk of patient mortality and morbidity.
PAREXEL Informatics Mergers and Acquisitions (M&A) Activities
In 2017, Parexel Informatics was acquired by Pamplona Capital for $5 billion. PAREXEL leadership expects with the acquisition, PAREXEL company to be in a better position for growth and success.
PAREXEL Informatics Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying PAREXEL Informatics applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of PAREXEL Informatics and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified Parexel Biotech, IMPACT CTMS customers.
PAREXEL Informatics Overview
Ownership: - Pamplona Capital Management
Number of Employees: 18660
Functional Markets: ERP Services and Operations Management,
Key Verticals: Life Sciences,
PAREXEL Informatics Key Enterprise and Cloud Applications
Parexel Biotech, IMPACT CTMS
PAREXEL Informatics Revenues, $M:
| Type/Year | 2018 | 2019 | YoY Growth, % |
|---|---|---|---|
| Total Revenues, $M | Subscribe | Subscribe | Subscribe |
| Enterprise Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
| Cloud Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
PAREXEL Informatics Revenue Breakdown By Type, $M:
| Type | License | Services | Hardware | Support & Maintenance | SaaS |
|---|---|---|---|---|---|
| % of Total Revenues | Subscribe | Subscribe | Subscribe | Subscribe | Subscribe |
| Revenues, $M | Subscribe | Subscribe | Subscribe | Subscribe | Subscribe |
PAREXEL Informatics Enterprise Applications Revenues By Functional Markets, $M:
PAREXEL Informatics Enterprise Applications Revenues By Verticals, $M:
PAREXEL Informatics Revenues By Region, $M
| Region | % of Total Revenues | 2019 Total Revenues, $M | 2019 Enterprise Applications Revenues, $M | 2019 Cloud Applications Revenues, $M |
|---|---|---|---|---|
| Americas | Subscribe | Subscribe | Subscribe | Subscribe |
| EMEA | Subscribe | Subscribe | Subscribe | Subscribe |
| APAC | Subscribe | Subscribe | Subscribe | Subscribe |
| Total | Subscribe | Subscribe | Subscribe | Subscribe |
PAREXEL Informatics Direct vs Indirect sales
| Region | Direct Sales | Indirect Sales | Total |
|---|---|---|---|
| Type % | Subscribe | Subscribe | Subscribe |
| Revenues, $M | Subscribe | Subscribe | Subscribe |
PAREXEL Informatics Customers - Breakdown by Geo, Size, Vertical and Product
List of Verified PAREXEL Informatics Customers
No. of PAREXEL Informatics Customers: x
No. of PAREXEL Informatics Enterprise Applications Customers: x
No. of PAREXEL Informatics Cloud Customers: x
No. of PAREXEL Informatics Cloud Subscribers: x
Pfizer, Merck, Almirall, Sanofi Pasteur, and Veeda Oncology are among Perceptive's key customers. In addition, Perceptive's DataLabs Electronic Data Capture (EDC) solution has been implemented by 15 of the top 35 global biopharmaceutical companies. Since the market introduction of LIQUENT InSight in 2004, more than 40 companies (including 14 of the top 20 pharmaceutical companies) have selected the LIQUENT InSight platform as their single source of regulatory information.
The IMPACT solution is the world's most utilized enterprise clinical trial management system (CTMS), with over 26,000 end users. PAREXEL was initially focused on supporting German and Japanese pharmaceutical firms, Parexel has expanded and now has clients in more than 100 countries worldwide.
PAREXEL Informatics Market Opportunities, M&A and Geo Expansions
With the help of its parent PAREXEL, Perceptive was able to market its software solutions to emerging and mid-size biopharmaceutical companies, advising them on best-practices strategies to maximize efficiencies and support more effective decision-making in clinical development and commercialization.
In September 2018, PAREXEL and Datavant partnered to enhance clinical study design and operations, as well as the generation of real-world evidence. As part of PAREXEL's focus on providing innovative scientific and clinical data strategies, the collaboration will enable the linking of healthcare data from a variety of real-world and clinical study data sources to improve drug development and commercialization processes. Datavant's technology enables the linking of traditional healthcare data sources including electronic medical records (EMRs), claims, and diagnostics with additional emerging sources, such as genomics, socioeconomic data, data from wearable devices, behavioral data and more.
The two companies also aim to advance hybrid study delivery to help life science companies more effectively generate evidence and demonstrate product value. A recent report released by the Economist Intelligence Unit and commissioned by PAREXEL found that drugs developed using real-world data had a 21 percent higher likelihood of launch, and real-world data studies resulted in reduced recruitment time. The report also identified advanced data analytics - including the sharing of data across established siloes as a key enabler to innovation in drug development and commercialization.
PAREXEL Informatics Risks and Challenges
Consolidation among the big pharmas could impact long-term growth for Parexel.
PAREXEL Informatics Ecosystem, Partners, Resellers and SI
Headquartered near Boston, Massachusetts, PAREXEL has offices in 82 locations in 51 countries around the world, and had approximately 18660 employees. Among its partners are, Clinical Ink, Cytel, ERT, Formedix, HighPoint Solutions, IBM, iCardiac Technologies, Metrics Champion Consortium, Microsoft, Tessella, TIBCO, pharmaSOL, Catalen. PAREXEL is on its way to strengthen its drug development and commercialization in Asia/Pacific through a new Hong Kong presence established by its strategic healthcare consulting Health Advances subsidiary.
PAREXEL Informatics Cloud Infrastructure Insights
Subscribe to read more about:
- PAREXEL Informatics Public Cloud and Infrastructure (IaaS)
- PAREXEL Informatics Platform (PaaS)
- PAREXEL Informatics Application Delivery
- PAREXEL Informatics Private Cloud and Data Centers
Research Methodology
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:
https://www.appsruntheworld.com/About Ushttps://www.appsruntheworld.com/taxonomy
https://www.appsruntheworld.com/FAQ
Copyright © 2021, APPS RUN THE WORLD